Miltenyi Biomedicine Gmbh

This study tests a treatment called MB-CART19.1 for people with severe systemic lupus erythematosus (SLE) that has not improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack disease-causing cells. The goal is to r…

This study tests a new treatment for people with lupus, scleroderma, or certain muscle diseases. The treatment uses a patient's own immune cells, modified to find and attack faulty B cells that drive the disease. About 24 adults will receive the therapy after a short course of ch…

This study tests a new treatment called MB-CART2019.1 for people with active multiple sclerosis (MS) that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack harmful immune cells driving MS. The goal is …

This trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack leukemia cells. Th…

This study tests a new treatment called MB-CART2019.1 in children and teens (ages 6 months to under 18) with B-cell cancers that came back or didn't respond to prior treatments. The therapy uses specially engineered immune cells to attack the cancer. The main goals are to see if …

This study tests a new treatment for people with a fast-growing blood cancer called diffuse large B cell lymphoma that has come back or not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are genetically modified to recognize an…

This study tests a new treatment called MB-CART2019.1, which uses a patient's own immune cells to fight a type of blood cancer called diffuse large B-cell lymphoma. It is for people whose cancer has come back or not responded to treatment and who cannot have a stem cell transplan…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, blood cell counts, growth, and overall health over time. The goal is to understand the long-term safety of these treatments.